Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
-
Correspondence: Carlos L Arteaga carlos.arteaga@vanderbilt.edu
Breast Cancer Res 2003, 5:96-100 doi:10.1186/bcr574
Accesses
- Last 30 days: 69 accesses
- Last 365 days: 617 accesses
- All time: 5565 accesses